Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Glutamine antagonist

DRUG CLASS:

Glutamine antagonist

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B
NFE2L2 mutation + STK11 mutation	Non Small Cell Lung Cancer	NFE2L2 mutation + STK11 mutation	Non Small Cell Lung Cancer	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B
NFE2L2 mutation	Non Small Cell Lung Cancer	NFE2L2 mutation	Non Small Cell Lung Cancer	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B
KEAP1 mutation	Lung Adenocarcinoma	KEAP1 mutation	Lung Adenocarcinoma	DRP-104 Sensitive: D – Preclinical DRP-104 Sensitive : D	DRP-104 Sensitive: D – Preclinical DRP-104 Sensitive : D
MYC expression	Medulloblastoma	MYC expression	Medulloblastoma	JHU395 Sensitive: D – Preclinical JHU395 Sensitive : D	JHU395 Sensitive: D – Preclinical JHU395 Sensitive : D
NF1 mutation	Neurofibrosarcoma	NF1 mutation	Neurofibrosarcoma	DR6MP + JHU395 Sensitive: D – Preclinical DR6MP + JHU395 Sensitive : D	DR6MP + JHU395 Sensitive: D – Preclinical DR6MP + JHU395 Sensitive : D
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	DRP-104 Sensitive: D – Preclinical DRP-104 Sensitive : D	DRP-104 Sensitive: D – Preclinical DRP-104 Sensitive : D